LabShares Newton offers free space for COVID-19 research
LabShares Newton is offering free, fully equipped biosafety level 2 lab space, facilities, and resources for researchers addressing the global COVID-19 pandemic, it announced on March 30.
Simulations Plus debuts COVID-19 consulting program
Medical simulation software company Simulations Plus announced that it has created a program to speed up consulting assistance to scientists working on COVID-19 research.
Atum gives labs free access to protein production platform
Atum has granted commercial and academic laboratories free access to its Leap-In Transposase protein production platform for use in creating tools and resources to battle the COVID-19 pandemic.
Xencor, Vir partner on COVID-19 antibodies research
Biopharmaceutical companies Xencor and Vir Biotechnology have entered into a technology licensing agreement to develop potential antibody-based treatments for patients with COVID-19.
Vycellix, Avectas partner for product development
Vycellix and Avectas have unveiled plans to collaborate on the development of cell-based immunotherapeutic products.
COVID-19 causes long-term disruptions to clinical trials
New survey results suggest that clinical trials are experiencing significant roadblocks associated with COVID-19. These could ultimately result in a slowdown of global drug development, according to Clinical Research IO.
Twist's SARS-CoV-2 quality controls added to FDA materials
Twist Bioscience's synthetic SARS-CoV-2 RNA quality controls for the development, verification, and validation of diagnostic tests for SARS-CoV-2 are now included in the U.S. Food and Drug Administration's (FDA) reference materials.
Frontera supercomputer aids COVID-19 drug development
Scientists are urgently working to build the first complete all-atom model of the SARS-CoV-2 coronavirus envelope, estimated to contain over 200 million atoms. This work was conducted as a collaboration between the Amaro Lab of the University of California, San Diego and the National Science Foundation-funded Frontera supercomputer at the University of Texas at Austin.
Dynavax, Clover partner for protein-based COVID-19 vaccine
A new research collaboration between Dynavax Technologies and Clover Biopharmaceuticals aims to develop a vaccine candidate to prevent COVID-19. The partnership, announced on March 24, will advance Clover's vaccine candidate, COVID-19 S-Trimer, with Dynavax providing its technical expertise and CpG 1018, a proprietary toll-like receptor 9 agonist adjuvant.
TriNetX updates platform to support COVID-19 research
Global health research network TriNetX said that it has updated its real-world data platform to incorporate specific terminology for COVID-19 test results.